{
    "clinical_study": {
        "@rank": "14890", 
        "arm_group": {
            "arm_group_label": "DA-EPOCH", 
            "arm_group_type": "Experimental", 
            "description": "Infused agents:\nEtoposide     50 mg/m2/day  CI24h  d1-d4; Doxorubicin   10 mg/m2/day  CI24h  d1-d4; Vincristine   0.4mg/m2/day  CI24h  d1-d4;\nBolus agents:\nRituximab(B-NHL)  375 mg/m2/day  IV  d0; Cyclophosphamide  750 mg/m2/day  IV  d5 ; Prednisone        60 mg/m2/bid   oral or IV  d1-d5;\nThe details of dose adjustment are described in ref 1.\nIf enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
        }, 
        "brief_summary": {
            "textblock": "The major purpose of this clinical study is to assess clinical outcome of dose-adjusted\n      EPOCH regimen for patients with non-Hodgkin's lymphoma(NHL)-associated hemophagocytic\n      lymphohistiocytosis"
        }, 
        "brief_title": "Trial of DA-EPOCH Regimen for NHL With HLH", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "NHL With Hemophagocytic Lymphohistiocytosis", 
        "condition_browse": {
            "mesh_term": [
                "Lymphohistiocytosis, Hemophagocytic", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "Lymphoma-associated hemophagocytic lymphohistiocytosis(LA-HLH) has a high fatality rate and\n      the worst outcome. The major cause of LA-HLH is aggressive non-Hodgkin's lymphoma(NHL),\n      especially T/NKT cell lymphomas. Until now, there is no recommended therapeutic schedule for\n      this fatal disease. Dose-adjusted(DA) EPOCH (etoposide, prednisone, vincristine,\n      cyclophosphamide, and doxorubicin) shows effective activity in patients with  aggressive\n      NHL. The investigators therefore developed DA-EPOCH regimen to treat non-Hodgkin's lymphoma\n      with hemophagocytic lymphohistiocytosis and assess its clinical outcome including safety and\n      efficacy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed non-Hodgkin's lymphoma;\n\n          2. Patients whose clinical findings satisfy either of HLH 2004 standard or ASH2009\n             standard:\n\n             HLH2004 standard at least 5 criteria out of the   following: Fever \u2265 38.5 \u2103 for \u2265 7\n             days; hepatosplenomegaly; Cytopenias affecting \u2265 2 of 3 lineages in PB Hb < 9 g/L\n             Platelet < 100 x   109 /L ANC < 1.0 x 109 /L; Hypertriglyceridemia and/or\n             hypofibrinogenemia (fasting triglycerides \u2265 265 mg/dL, fibrinogen \u2264 1.5 g/L);\n             Hemophagocytosis in BM or spleen or LN; Low or absent NK-cell activity ( according to\n             local laboratory reference); Serum-ferritin \u2265 500 mcg/L ; Soluble CD25(sIL-2\n             receptor) \u2265 2,400 U/ml ;\n\n          3. New-diagnosed and untreated;\n\n          4. Understand and voluntarily sign an informed consent form, able to adhere to the study\n             visit schedule and other protocol requirements.\n\n        ASH2009 Standard\n\n          1. .At least 3 of 4:\n\n               1. Fever\n\n               2. Splenomegaly\n\n               3. Cytopenias (minimum 2 cell lines reduced)\n\n               4. Hepatitis\n\n          2. . And at least 1 of 4:\n\n               1. Hemophagocytosis\n\n               2. \u2191 Ferritin\n\n               3. \u2191 sIL2R\u03b1 (age based)\n\n               4. Absent or very decreased NK function 4. Other results supportive of HLH\n                  diagnosis:\n\n               1. Hypertriglyceridemia\n\n               2. Hypofibrinogenemia\n\n               3. Hyponatremia\n\n        Exclusion Criteria:\n\n          1. Primary HLH.\n\n          2. HLH from rheumatic disorder (such as SLE, AOSD, antiphospholipid antibody syndrome)\n\n          3. Pregnancy (as determined by serum or urine test) or active breast feeding\n\n          4. Concomitant malignancy other than non-Hodgkin's lymphoma and need to treat;\n\n          5. Concomitant with other hematologic diseases(such as leukemia,hemophilia primary\n             myelofibrosis) which investigator it unsuitable to be enrolled into this clinical\n             trial;\n\n          6. Any potential drug abuse, medical, psychological or social conditions which may\n             disturb this investigation and assessment.\n\n          7. In any conditions which investigator considered ineligible for this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818908", 
            "org_study_id": "JSPH-HLH-001"
        }, 
        "intervention": {
            "arm_group_label": "DA-EPOCH", 
            "description": "DA-EPOCH regimen", 
            "intervention_name": "DA-EPOCH", 
            "intervention_type": "Drug", 
            "other_name": [
                "Infused agents", 
                "Etoposide", 
                "Doxorubicin", 
                "Vincristine", 
                "Cyclophosphamide", 
                "Prednisone", 
                "Rituximab(B-NHL)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Rituximab", 
                "Doxorubicin", 
                "Etoposide", 
                "Prednisone", 
                "Vincristine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "non-Hodgkin's lymphoma", 
            "hemophagocytic lymphohistiocytosis", 
            "DA-EPOCH", 
            "rituximab"
        ], 
        "lastchanged_date": "March 23, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Min Zhou, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "ChangZhou", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "213011"
                    }, 
                    "name": "ChangZhou No.2 People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Min Zhou, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Liang Yu, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "HuaiAn", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "223300"
                    }, 
                    "name": "HuaiAn First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Liang Yu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "LEI FAN, Dr.", 
                    "phone": "86 25 6813 6034"
                }, 
                "facility": {
                    "address": {
                        "city": "NanJing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "JiangSu Province Hospital"
                }, 
                "investigator": {
                    "last_name": "WEI XU, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yun Zhuang, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "WuXi", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "214023"
                    }, 
                    "name": "WuXi People's Hospital"
                }, 
                "investigator": {
                    "last_name": "YunFeng Shen, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Study of Dose-adjusted EPOCH Regimen for Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis", 
        "overall_contact": {
            "email": "fanlei_fl@yahoo.com.cn", 
            "last_name": "LEI FAN, M.D., Ph.D.", 
            "phone": "+86 25 6813 6034"
        }, 
        "overall_official": {
            "affiliation": "Jiangsu Province Hospital", 
            "last_name": "Wei Xu, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "overall response rate after treated by DA-EPOCH regimen", 
                "measure": "overall response rate", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "To determine the median time to overall response", 
                "measure": "Time to Response", 
                "safety_issue": "No", 
                "time_frame": "four weekd after treatment of DA-EPOCH"
            }
        ], 
        "reference": [
            {
                "PMID": "11929754", 
                "citation": "Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685-93."
            }, 
            {
                "PMID": "16937360", 
                "citation": "Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31."
            }, 
            {
                "PMID": "18378569", 
                "citation": "Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008 Jun 1;26(16):2717-24. Epub 2008 Mar 31."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818908"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jiangsu Province Hospital", 
            "investigator_full_name": "WEI XU", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "progression free survival after treatment of DA-EPOCH regimen", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "overall survival after treatment of DA-EPOCH regimen", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "Number of Participants with Adverse Events, and evaluated standard is according to common terminology criteria adverse events(CTCAE) version 4.0", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 30 days after last dose of treatment"
            }
        ], 
        "source": "Jiangsu Province Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Province Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}